Ping Liu

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. pmc Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, New London, CT 06320, USA
    Antimicrob Agents Chemother 51:3617-26. 2007
  2. ncbi request reprint Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis
    Ping Liu
    Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 58:4727-36. 2014
  3. ncbi request reprint Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis
    Ping Liu
    Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 58:4718-26. 2014
  4. pmc Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections
    Ping Liu
    Clinical Pharmacology, Specialty Care, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 57:466-74. 2013
  5. pmc Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults
    Timothy A Driscoll
    Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, North Carolina 06340, USA
    Antimicrob Agents Chemother 55:5770-9. 2011
  6. pmc Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults
    Timothy A Driscoll
    Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Antimicrob Agents Chemother 55:5780-9. 2011
  7. ncbi request reprint Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, MS6025 A3232, New London, CT 06320, USA
    J Clin Pharmacol 48:73-84. 2008
  8. pmc Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    Antimicrob Agents Chemother 51:110-8. 2007
  9. ncbi request reprint Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin
    Richa Chandra
    Clinical R and D, Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Clin Pharmacokinet 46:247-59. 2007
  10. doi request reprint Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease
    Chieko Muto
    Clinical Pharmacology, Clinical Research, Pfizer Inc, Tokyo, Japan
    J Antimicrob Chemother 66:165-74. 2011

Collaborators

  • Bharat Damle
  • Chieko Muto
  • Annie F Fang
  • Kuan Gandelman
  • William Curatolo
  • Lauren P Shearman
  • Linus S Lin
  • Koji Chiba
  • Timothy A Driscoll
  • Yi Yang Hu
  • Lolie C Yu
  • Haydar Frangoul
  • Robert A Krance
  • Alice Baruch
  • Jeffrey Blumer
  • Can Xia Liu
  • Tung M Fong
  • Brigitte Wrede
  • Richa Chandra
  • Minjun Chen
  • Cheng Liu
  • Yun kun Huang
  • Shanchun Zhang
  • Chuan Li
  • Michael L Graham
  • Eneida Nemecek
  • Donald K Murphey
  • Scott M Bradfield
  • Antonio Arrieta
  • Eneida R Nemecek
  • Yan Min Bao
  • Ya Yan Zhou
  • Hong Yu
  • James P Jewell
  • Kim M Rosko
  • Charles Xie
  • D Euan Macintyre
  • Suoyu S Xu
  • Robert Labadie
  • Jeannine Fisher
  • Hongbo Qi
  • Lisa J Benincosa
  • Jeanne D Breen
  • Julie Lao
  • Amarnath Sharma
  • Williams K Hagmann
  • Lex H T Van der Ploeg
  • Junying Wang
  • Xiao Ming Guan
  • Donald J Marsh
  • D Sloan Stribling
  • Jing C Xiao
  • Rebecca J Benner
  • Chun Pyn Shen
  • Johannes Ernst Alexander Wolff
  • Mark T Goulet
  • Barbara Francis
  • Alison M Strack
  • Shrenik K Shah
  • Thomas J Lanza
  • Xinchun Tong
  • Yue Feng
  • Jiye Cheng
  • Mingming Su
  • Jian Jiang
  • Yumin Liu
  • Yijiang Lai
  • Liping Zhao
  • Wei Jia
  • Xiping Xu
  • Chang Qing Zhao
  • Hui Ming Xue
  • Shanqun Jiang
  • Houxun Xing
  • Xiumei Hong
  • Cheng Yu
  • Fang Xu
  • Jian Cui
  • Bin Huang
  • Qingxiang Shao
  • Jieyu Dai
  • Hao Yuan
  • Meiyun Zhang
  • Jiang Zhen
  • Fajun Nan
  • Zhouhua Ji

Detail Information

Publications30

  1. pmc Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, New London, CT 06320, USA
    Antimicrob Agents Chemother 51:3617-26. 2007
    ....
  2. ncbi request reprint Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis
    Ping Liu
    Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 58:4727-36. 2014
    ..This study was registered on ClinicalTrials.gov (NCT00531479). ..
  3. ncbi request reprint Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis
    Ping Liu
    Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 58:4718-26. 2014
    ..This study was approved by the appropriate institutional review boards or ethics committees and registered on ClinicalTrials.gov (NCT00531479). ..
  4. pmc Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections
    Ping Liu
    Clinical Pharmacology, Specialty Care, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 57:466-74. 2013
    ..g., area under the curve < 40 mg · h/liter in ICC patients). There was no association between anidulafungin exposure and the treatment-related adverse events or all-causality hepatic laboratory abnormalities...
  5. pmc Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults
    Timothy A Driscoll
    Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, North Carolina 06340, USA
    Antimicrob Agents Chemother 55:5770-9. 2011
    ..Safety of voriconazole in children was consistent with the known safety profile of voriconazole...
  6. pmc Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults
    Timothy A Driscoll
    Department of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Antimicrob Agents Chemother 55:5780-9. 2011
    ..g., 12 to 14 years old) may need to receive higher doses to match the adult exposures. Safety of voriconazole in adolescents was consistent with the known safety profile of voriconazole...
  7. ncbi request reprint Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, MS6025 A3232, New London, CT 06320, USA
    J Clin Pharmacol 48:73-84. 2008
    ..Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics...
  8. pmc Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    Antimicrob Agents Chemother 51:110-8. 2007
    ..Nevertheless, caution should be exercised when voriconazole is coadministered with methadone due to the increase in (R)-methadone exposure, which in turn may require a dose reduction of methadone...
  9. ncbi request reprint Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin
    Richa Chandra
    Clinical R and D, Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Clin Pharmacokinet 46:247-59. 2007
    ..Of these, five pivotal studies are described here...
  10. doi request reprint Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease
    Chieko Muto
    Clinical Pharmacology, Clinical Research, Pfizer Inc, Tokyo, Japan
    J Antimicrob Chemother 66:165-74. 2011
    ....
  11. doi request reprint Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules
    William Curatolo
    Pharmaceutical Sciences, PharmaTherapeutics, Pfizer Global R and D, Groton, Connecticut 06340, USA
    Pharm Res 28:1531-9. 2011
    ..Azithromycin gelatin capsules were formulated with "superdisintegrants" to provide fast-dissolving capsules, and HPMC capsule shells were substituted for gelatin capsule shells, in an effort to eliminate the food effect...
  12. pmc Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media
    Ping Liu
    Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 55:5022-6. 2011
    ..These results indicated that a 60-mg/kg single dose of ER azithromycin provides similar or greater systemic exposure in children than the 30-mg/kg single dose of IR azithromycin...
  13. pmc Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis
    Ping Liu
    Clinical Pharmacology, Specialty Care, Pfizer Inc, Groton, Connecticut, USA
    Antimicrob Agents Chemother 57:1672-6. 2013
    ..3 and 105.9 mg · h/liter and 7.2 and 7.0 mg/liter, respectively. The pharmacokinetics of anidulafungin in ICU patients appeared to be comparable to those in the general patient population and healthy subjects at the same dosing regimen...
  14. pmc Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen
    Ping Liu
    Department of Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Ave, New London, CT 06320, USA
    Antimicrob Agents Chemother 51:103-9. 2007
    ..This "front-loading" of the dose on day 1 is safely achieved by the extended-release microsphere formulation, which maximizes the drug exposure at the time when the bacterial burden is likely to be highest...
  15. doi request reprint Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents
    Ping Liu
    Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China
    Bioorg Med Chem Lett 18:3261-5. 2008
    ..SAR clearly suggested that introduction of a biaryloxy side chain greatly enhanced the antifungal activity of triazole analogs against Candida species...
  16. ncbi request reprint Tissue penetration of cefpodoxime and cefixime in healthy subjects
    Ping Liu
    Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    J Clin Pharmacol 45:564-9. 2005
    ..Pharmacokinetic modeling was applied to describe the pharmacokinetic profiles in plasma and muscle. The study demonstrates that cefpodoxime shows greater tissue penetration than cefixime...
  17. ncbi request reprint [Influence of Fuzheng Huayu Capsules on abnormal amino acids spectrum in chronic liver diseases]
    Yun kun Huang
    Institute of Liver Disease, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    Zhonghua Gan Zang Bing Za Zhi 13:230-1. 2005
  18. ncbi request reprint Antimicrobial tissue concentrations
    Ping Liu
    Department of Pharmaceutics, College of Pharmacy, University of Florida, 1600 SW Archer Road, PO Box 100494, Gainesville, FL 32610, USA
    Infect Dis Clin North Am 17:599-613. 2003
    ..The optimal dosing regimens of antibiotics have an impact on patients' outcome and cost of therapy, and reduce the emergence of resistance...
  19. ncbi request reprint Liquid chromatography/tandem mass spectrometry for the determination of fluoxetine and its main active metabolite norfluoxetine in human plasma with deuterated fluoxetine as internal standard
    Chuan Li
    Shanghai Institute of Materia Medica, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road, Shanghai 200031, China
    Rapid Commun Mass Spectrom 16:1844-50. 2002
    ..999. The limit of detection was 0.1 ng/mL for plasma F and NF. Taking the plasma sample size (200 micro L) into account the new method for determination of F and NF is more sensitive than those described previously...
  20. ncbi request reprint [Investigation on indication of fuzheng huayu capsule against hepatic fibrosis and its non-invasive efficacy evaluation parameters: data analysis of liver biopsy of 50 patients with chronic hepatitis B before and after treatment]
    Yi Yang Hu
    Institute of Liver Disease, Shanghai University of Traditional Chinese Medicine, Shanghai
    Zhongguo Zhong Xi Yi Jie He Za Zhi 26:18-22. 2006
    ..To investigate the indication of Fuzheng Huayu Capsule (FHC) against hepatic fibrosis and its non-invasive efficacy evaluation parameters...
  21. ncbi request reprint [Pulmonary function of healthy children at ages of 1-48 months in Shenzhen area]
    Can Xia Liu
    Shenzhen Childre s Hospital, Shenzhen, Guangdong 518026, China
    Zhongguo Dang Dai Er Ke Za Zhi 10:28-30. 2008
    ..To study the development of pulmonary function of healthy children between 1-48 months...
  22. ncbi request reprint Metabonomic study of aristolochic acid-induced nephrotoxicity in rats
    Minjun Chen
    School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200030, China
    J Proteome Res 5:995-1002. 2006
    ....
  23. ncbi request reprint The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits
    Ping Liu
    Department of Chemistry and Microbacteria Detection, College of Public Health, Shandong University, Wenhuaxilu 44, Jinan 250012, PR China
    J Inorg Biochem 99:1733-7. 2005
    ..At the end of experiment the aluminum contents of bone, kidney, liver and brain in Al+DE were significantly lower than that in Al-only rabbits. The copper, zinc, manganese contents were not affected by deferiprone administration...
  24. ncbi request reprint Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
    Linus S Lin
    Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA
    J Med Chem 49:7584-7. 2006
    ..These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity...
  25. ncbi request reprint Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents
    Tung M Fong
    Department of Metabolic Disorders, Merck Research Laboratories, R80M 213, P O Box 2000, Rahway, NJ 07065, USA
    J Pharmacol Exp Ther 321:1013-22. 2007
    ..These studies demonstrated that MK-0364 is a highly potent and selective CB1R inverse agonist and that it is orally active in rodent models of obesity...
  26. ncbi request reprint Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats
    Ping Liu
    Department of Pharmaceutics, College of Pharmacy, University of Florida, 1600 SW Archer Road, P O BOX 100494, Gainesville, FL 32610, USA
    Eur J Pharm Sci 25:439-44. 2005
    ....
  27. ncbi request reprint Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors
    Brigitte Wrede
    Department of Pediatric Oncology, St Hedwig Children s Hospital, University of Regensburg, Steinmetzstr 1 3, Regensburg 93049, Germany
    J Neurooncol 85:345-51. 2007
    ..Choroid plexus carcinomas (CPC) are rare brain tumors with a dismal prognosis. Although the role of surgery has been well established, the question of whether chemotherapy improves the prognosis is still under discussion...
  28. ncbi request reprint Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B
    Ping Liu
    Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    World J Gastroenterol 11:2892-9. 2005
    ..To study the efficacy and safety of Fuzhenghuayu capsule (FZHY capsule, a capsule for strengthening body resistance to remove blood stasis) against liver fibrosis due to chronic hepatitis B...
  29. ncbi request reprint Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension
    Shanchun Zhang
    School of Life Science, University of Science and Technology of China, Hefei, Anhui, China
    Methods Find Exp Clin Pharmacol 27:173-8. 2005
    ..The metabolic rate of irbesartan in current smokers was slower than those in nonsmokers and former smokers...
  30. ncbi request reprint Interstitial tissue concentrations of cefpodoxime
    Ping Liu
    Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    J Antimicrob Chemother 50:19-22. 2002
    ..4 mg x h/L versus 7.3 mg x h/L). These findings indicate that, taking into account pharmacokinetic/pharmacodynamic considerations, cefpodoxime is likely to be more efficacious than cefixime, due to its greater tissue penetration...